The Impact of Anabolic Androgenic Steroids on Organ Failure in Bodybuilders - a Review of Actual Literature
DOI:
https://doi.org/10.12775/QS.2025.41.60236Keywords
anabolic androgenic steroids, depression, left ventricular dysfunction, acute kidney injury (AKI)Abstract
Anabolic-Androgenic Steroids (AAS), despite their therapeutic applications in the management of selected medical conditions, are increasingly being misused for non-medical purposes—particularly among bodybuilders and individuals seeking to enhance their physique. This review article examines the impact of chronic AAS administration on the functionality of selected human organs and physiological systems.
Based on current clinical and preclinical evidence, the biological mechanisms of AAS action are discussed, with particular emphasis on their affinity for androgen receptors and modulation of intracellular signaling pathways. The paper presents robust evidence of the adverse effects associated with AAS use, including cardiomyopathies, renal dysfunction, neuropsychiatric disorders (notably increased aggression and depressive symptoms), hepatotoxicity, and metabolic disturbances.
Special attention is given to the potential mechanisms underlying AAS-induced toxicity, as well as the reversibility of the observed pathological alterations. The findings underscore the necessity for intensified health education and systematic monitoring of individuals using AAS, due to the elevated risk of irreversible, multisystem complications.
References
1. Kanayama, G., Hudson, J. I., & Pope, H. G. Jr. (2015). Illicit anabolic–androgenic steroid use. Hormones and Behavior, 76, 4–13.
2. Harrison G. Pope, Ruth I. Wood, Alan Rogol, Fred Nyberg, Larry Bowers, Shalender Bhasin, Adverse Health Consequences of Performance-Enhancing Drugs: An Endocrine Society Scientific Statement, Endocrine Reviews, Volume 35, Issue 3, 1 June 2014, Pages 341–375, https://doi.org/10.1210/er.2013-1058
3. Eberhard Nieschlag, Elena Vorona, MECHANISMS IN ENDOCRINOLOGY: Medical consequences of doping with anabolic androgenic steroids: effects on reproductive functions, European Journal of Endocrinology, Volume 173, Issue 2, Aug 2015, Pages R47–R58, https://doi.org/10.1530/EJE-15-0080
4. Baggish, A. L., Weiner, R. B., Kanayama, G., Hudson, J. I., Lu, M. T., Hoffmann, U., & Pope, H. G. Jr. (2010). Long‐term anabolic‐androgenic steroid use is associated with left ventricular dysfunction. Circulation: Heart Failure, 3(4), 472–476. https://doi.org/10.1161/CIRCHEARTFAILURE.109.931063
5. Shahidi, N. T. (2023). Anabolic androgenic steroids and the androgen receptor: Insights into structure, function, and clinical implications. Endocrine Reviews, 44(1), 55–77.
6. Basaria, S., & Bhasin, S. (2021). Androgen Action in Muscle and Bone. Journal of Clinical Endocrinology & Metabolism, 106(4), 1068–1078.
7. Schweizer, L., Ripperger, T., & Stalla, G. K. (2022). Dihydrotestosterone in anabolic–androgenic steroid action: Lessons from clinical and molecular studies. Hormone Molecular Biology and Clinical Investigation, 43(2), 20220008.
8. Kicman, A. T., Birzniece, V., & Handelsman, D. J. (2021). The role of aromatization in the anabolic actions of androgens. Steroids, 172, 108882.
9. Gómez, R., Ropero, A. B., & Garrido-Gracia, J. C. (2023). Non-genomic actions of testosterone: facts and perspectives. Molecular and Cellular Endocrinology, 567, 111946.
10. Dubois, V., Laurent, M. R., Sinnesael, M., Cielen, N., Helsen, C., Clinckemalie, L., ... & Claessens, F. (2022). Aging and androgen receptor signaling in skeletal muscle and mesenchymal stem cells. Frontiers in Endocrinology, 13, 1059473.
11. Guida, C, De Castro, A, Ferreira, A. et al. EFFECTS OF ANABOLIC ANDROGENIC STEROIDS IN ATHLETES ON LEFT VENTRICLE SYSTOLIC AND DIASTOLIC FUNCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS. JACC. 2024 Apr, 83 (13_Supplement) 1573. https://doi.org/10.1016/S0735-1097(24)03563-0.
12. Abdullah R, Bjørnebekk A, Hauger LE, Hullstein IR, Edvardsen T, Haugaa KH, Almaas VM. Severe biventricular cardiomyopathy in both current and former long-term users of anabolic-androgenic steroids. Eur J Prev Cardiol. 2024 Mar 27;31(5):599-608. doi: 10.1093/eurjpc/zwad362. PMID: 37992194.
13. Fadah K, Gopi G, Lingireddy A, Blumer V, Dewald T, Mentz RJ. Anabolic androgenic steroids and cardiomyopathy: an update. Front Cardiovasc Med. 2023 Jul 26;10:1214374. doi: 10.3389/fcvm.2023.1214374. PMID: 37564909; PMCID: PMC10412093.
14. Laust Frisenberg Buhl, Louise Lehmann Christensen, Rikke Hjortebjerg, Selma Hasific, Clara Hjerrild, Stefan Harders, Mads Lillevang-Johansen, Dorte Glintborg, Marianne S. Andersen, Mario Thevis, Caroline Kistorp, Jon Jarløv Rasmussen, Jes S. Lindholt, Axel Diederichsen, Jan Frystyk. Impact of Androgenic Anabolic Steroids on Cardiovascular Health in Men and Women. medRxiv 2024.11.18.24317516; doi:https://doi.org/10.1101/2024.11.18.24317516.
15. Tungesvik HM, Bjørnebekk A, Hisdal J. Impaired vascular function among young users of anabolic-androgenic steroids. Sci Rep. 2024 Aug 19;14(1):19201. doi: 10.1038/s41598-024-70110-5. PMID: 39160232; PMCID: PMC11333575.
16. Christou, G.A., et al. (2020). "Sudden cardiac death in anabolic-androgenic steroid users: A literature review". Forensic Sci Int, 312, 110308.
17. Bjørnebekk, A., et al. (2017). Structural brain imaging of long-term anabolic-androgenic steroid users and nonusing weightlifters. Biological Psychiatry, 82(4), 294–302. https://doi.org/10.1016/j.biopsych.2016.06.017.
18. Westlye, L. T., et al. (2017). Brain connectivity aberrations in anabolic-androgenic steroid users. NeuroImage: Clinical, 13, 62–69. https://doi.org/10.1016/j.nicl.2016.11.014.
19. Zelleroth, S., et al. (2021). Structurally different anabolic androgenic steroids reduce neurite outgrowth and neuronal viability in primary rat cortical cell cultures. J Steroid Biochem Mol Biol, 210, 105863. https://doi.org/10.1016/j.jsbmb.2021.105863.
20. Bertozzi, G., et al. (2018). The role of anabolic androgenic steroids in disruption of the physiological function in discrete areas of the central nervous system. Mol Neurobiol, 55(7), 5548–5556. https://doi.org/10.1007/s12035-017-0774-1.
21. Clark, A. S., & Henderson, L. P. (2016). Behavioral and physiological responses to anabolic-androgenic steroids. Neurosci Biobehav Rev, 60, 411–420. https://pubmed.ncbi.nlm.nih.gov/28971285/.
22. Chegeni R, Pallesen S, McVeigh J, Sagoe D. Anabolic-androgenic steroid administration increases self-reported aggression in healthy males: a systematic review and meta-analysis of experimental studies. Psychopharmacology (Berl). 2021 Jul;238(7):1911-1922. doi: 10.1007/s00213-021-05818-7. Epub 2021 Mar 20. PMID: 33745011; PMCID: PMC8233285.
23. Nelson, B.S., Hildebrandt, T. & Wallisch, P. Anabolic–androgenic steroid use is associated with psychopathy, risk-taking, anger, and physical problems. Sci Rep 12, 9133 (2022). https://doi.org/10.1038/s41598-022-13048-w
24. Karagun B, Altug S. Anabolic-androgenic steroids are linked to depression and anxiety in male bodybuilders: the hidden psychogenic side of anabolic androgenic steroids. Ann Med. 2024 Dec;56(1):2337717. doi: 10.1080/07853890.2024.2337717. Epub 2024 Apr 8. PMID: 38590148; PMCID: PMC11005876.
25. Gawad, Mohammed Abdel; Kalawy, Heba A.. Gym nephropathy ‘bodybuilding versus kidney damaging’. Journal of The Egyptian Society of Nephrology and Transplantation 19(4):p 124-128, Oct–Dec 2019. | DOI: 10.4103/jesnt.jesnt_32_19
26. Davani-Davari D, Karimzadeh I, Khalili H. The potential effects of anabolic-androgenic steroids and growth hormone as commonly used sport supplements on the kidney: a systematic review. BMC Nephrol. 2019 May 31;20(1):198. doi: 10.1186/s12882-019-1384-0. PMID: 31151420; PMCID: PMC6545019.
27. Ozkurt S, Ozakin E, Gungor H, Yalcin AU. Assessment of Renal Function of Bodybuilders Using Anabolic Androgenic Steroids and Diet Supplements. Cureus. 2023 Aug 7;15(8):e43058. doi: 10.7759/cureus.43058. PMID: 37680426; PMCID: PMC10481367.
28. Passaro R, D'Angiò P, Laurino S, Gigliotti G, Massa A, Mancini A, Gonnella A, Giammarino A, Borriello G. [Collapsing Glomerulopathy Secondary to Anabolic Steroids for Bodybuilding: A Case Series]. G Ital Nefrol. 2023 Oct 26;40(5):2023-vol5. Italian. PMID: 38010246.
29. Almukhtar SE, Abbas AA, Muhealdeen DN, Hughson MD. Acute kidney injury associated with androgenic steroids and nutritional supplements in bodybuilders(†). Clin Kidney J. 2015 Aug;8(4):415-9. doi: 10.1093/ckj/sfv032. Epub 2015 May 26. PMID: 26251708; PMCID: PMC4515889.
30. Lemiński, A.; Kubis, M.; Kaczmarek, K.; Gołąb, A.; Kazimierczak, A.; Kotfis, K.; Słojewski, M. When Bodybuilding Goes Wrong—Bilateral Renal Artery Thrombosis in a Long-Term Misuser of Anabolic Steroids Treated with AngioJet Rheolytic Thrombectomy. Int. J. Environ. Res. Public Health 2022, 19, 2122. https://doi.org/10.3390/ijerph19042122.
31. Tarashande Foumani A, Elyasi F. Oxymetholone-Induced Acute Renal Failure: A Case Report. Caspian J Intern Med. 2018 Fall;9(4):410-412. doi: 10.22088/cjim.9.4.406. PMID: 30510659; PMCID: PMC6230458.
32. Benjamin A, Anderson A, Zrelec S. Delayed rhabdomyolysis secondary to anabolic-androgenic steroid use. Clin Med (Lond). 2020 Nov;20(6):e260-e261. doi: 10.7861/clinmed.2020-0694. PMID: 33199332; PMCID: PMC7687328.
33. Farkash U, Shabshin N, Pritsch Perry M. Rhabdomyolysis of the deltoid muscle in a bodybuilder using anabolic-androgenic steroids: a case report. J Athl Train. 2009 Jan-Feb;44(1):98-100. doi: 10.4085/1062-6050-44.1.98. PMID: 19180225; PMCID: PMC2629047.
34. Petrovic A, Vukadin S, Sikora R, Bojanic K, Smolic R, Plavec D, Wu GY, Smolic M. Anabolic androgenic steroid-induced liver injury: An update. World J Gastroenterol. 2022 Jul 14;28(26):3071-3080. doi: 10.3748/wjg.v28.i26.3071. PMID: 36051334; PMCID: PMC9331524.
35. Arazi H. Effects of longitudinal abuse of anabolic steroids on liver enzymes activity and lipid profiles of male bodybuilders. Progr Nutr [Internet]. 2018 Sep. 23 ;20(3):323-8.
36. Patil V, Jothimani D, Harika K, Hakeem AR, Sachan D, Vij M, Rela M. Versatility of Anabolic Androgenic Steroid-Induced Hepatotoxicity. J Clin Exp Hepatol. 2022 Jan-Feb;12(1):216-221. doi: 10.1016/j.jceh.2021.03.003. Epub 2021 Mar 11. PMID: 35068803; PMCID: PMC8766528.
37. Tenório MCC, Paz CL, Valladares F, Guimarães Junior M, Sá CKC, Correia L. Effects of Low-to-Moderate Doses of Anabolic Steroids on Lipid Profile and Muscle Hypertrophy in Resistance Training Practitioners: A Systematic Review with Meta-Analysis. Int. J. Cardiovasc. Sci. 2021;34(5):531-4.
38. Perry JC, Schuetz TM, Memon MD, Faiz S, Cancarevic I. Anabolic Steroids and Cardiovascular Outcomes: The Controversy. Cureus. 2020 Jul 22;12(7):e9333. doi: 10.7759/cureus.9333. PMID: 32850208; PMCID: PMC7444848.
39. Tavares AS, Bellém F, Ferreira B, Leite B, Calixto C. Impact of supraphysiological doses of anabolic steroids on glucose and insulin levels in male bodybuilders: a systematic review. In: XVII SIEFLAS – Seminário Internacional de Educação Física, Lazer e Saúde, Escola Superior de Educação do Instituto Politécnico de Viana do Castelo, 17 a 19 de outubro de 2024.
40. Di Girolamo, F.G., Biasinutto, C., Mangogna, A. et al. Metabolic Consequences of Anabolic Steroids, Insulin, and Growth Hormone Abuse in Recreational Bodybuilders: Implications for the World Anti-Doping Agency Passport. Sports Med - Open 10, 28 (2024). https://doi.org/10.1186/s40798-024-00697-6
41. Vilar Neto JDO, da Silva CA, Bruno da Silva CA, et al. Anabolic androgenic steroid-induced hypogonadism, a reversible condition in male individuals? A systematic review. Andrologia. 2021; 53:e14062. https://doi.org/10.1111/and.14062
42. Mulawkar PM, Maheshwari PN, Gauhar V, et al. Use of Anabolic-Androgenic Steroids and Male Fertility: A Systematic Review and Meta-analysis. Journal of Human Reproductive Sciences. 2023 Oct-Dec;16(4):268-285. DOI: 10.4103/jhrs.jhrs_90_23. PMID: 38322636; PMCID: PMC10841926.
43. Deyssig R, Weissel M. Ingestion of androgenic-anabolic steroids induces mild thyroidal impairment in male body builders. J Clin Endocrinol Metab. 1993 Apr;76(4):1069-71. doi: 10.1210/jcem.76.4.8473383. PMID: 8473383.
44. Solanki P, Eu B, Smith J, Allan C, Lee K. Physical, psychological and biochemical recovery from anabolic steroid-induced hypogonadism: a scoping review. Endocr Connect. 2023 Oct 19;12(12):e230358. doi: 10.1530/EC-23-0358. PMID: 37855241; PMCID: PMC10620455.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Julia Marcinkowska, Mateusz Szymon Muras, Tomasz Lorenc, Maciej Michalik, Krzysztof Marcinkowski, Jakub Mikszta, Natalia Mikszta
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 230
Number of citations: 0
